TY - JOUR
T1 - Apolipoprotein e and Alzheimer disease
T2 - Risk, mechanisms and therapy
AU - Liu, Chia Chan
AU - Kanekiyo, Takahisa
AU - Xu, Huaxi
AU - Bu, Guojun
N1 - Funding Information:
Work in authors’ laboratories is supported by the NIH, the Alzheimer’s Association, the American Health Assistance Foundation, and Xiamen University Research Funds. We thank C. Stetler and O. Ross for critical reading of the manuscript before submission.
PY - 2013/2
Y1 - 2013/2
N2 - Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss Aβ-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E.
AB - Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss Aβ-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E.
UR - http://www.scopus.com/inward/record.url?scp=84873722367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873722367&partnerID=8YFLogxK
U2 - 10.1038/nrneurol.2012.263
DO - 10.1038/nrneurol.2012.263
M3 - Review article
C2 - 23296339
AN - SCOPUS:84873722367
SN - 1759-4758
VL - 9
SP - 106
EP - 118
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 2
ER -